Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AP1903 for GvHD after iCasp9-modified T-cell DLI
NCT01875237Phase 2Terminated
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Dec 2013
- Primary completion
- Mar 2017
- Modality
- Small Molecules, Cell Therapies
- Countries
- 1
01
Overview
A Phase 2 trial of rivogenlecleucel, rimiducid in hematologic malignancy, graft-versus-host disease (GVHD), sponsored by University of Texas MD Anderson Cancer Center. Started Dec 2013; status: terminated.
02
Drugs
rivogenlecleucelrimiducid
03
Conditions
hematologic malignancygraft-versus-host disease (GVHD)
Beyond the preview
Go deeper on NCT01875237.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01875237.